$57.5 Million is the total value of Asymmetry Capital Management, L.P.'s 20 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 47.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTCT | Buy | PTC THERAPEUTICS | $7,953,000 | +269.4% | 567,683 | +85.1% | 13.83% | +250.6% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $5,686,000 | +284.4% | 150,651 | +79.3% | 9.89% | +265.0% |
| Sell | BIO-RAD LABRATORIES | $5,027,000 | +13.3% | 30,687 | -1.1% | 8.74% | +7.5% | |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $4,576,000 | +264.9% | 618,317 | +169.3% | 7.96% | +246.4% |
| CNC | Sell | CENTENE CORP | $4,544,000 | -22.5% | 67,856 | -17.4% | 7.90% | -26.4% |
| IPXL | Buy | IMPAX LABORATORIES INC | $3,890,000 | +92.2% | 164,156 | +133.7% | 6.76% | +82.4% |
| UNH | Buy | UNITEDHEALTH GROUP INC | $3,882,000 | +16.3% | 27,728 | +17.3% | 6.75% | +10.3% |
| INCY | Buy | INCYTE CORP | $3,527,000 | +72.9% | 37,407 | +46.6% | 6.13% | +64.1% |
| JAZZ | Sell | JAZZ PHARMACEUTICALS | $3,429,000 | -38.6% | 28,229 | -28.6% | 5.96% | -41.7% |
| LLY | Sell | ELI LILLY & CO | $2,651,000 | -42.9% | 33,029 | -44.0% | 4.61% | -45.8% |
| Buy | IRONWOOD PHARMACEUTICALS | $2,378,000 | +49.9% | 149,720 | +23.4% | 4.14% | +42.3% | |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $1,906,000 | +36.7% | 37,644 | +22.7% | 3.31% | +29.8% |
| SGYPQ | Buy | SYNERGY PHARMACEUTICALS INC | $1,868,000 | +64.9% | 339,068 | +13.7% | 3.25% | +56.5% |
| EW | Sell | EDWARDS LIFESCIENCES CORP | $1,677,000 | -40.5% | 13,908 | -50.8% | 2.92% | -43.5% |
| New | NOVOCURE LTD | $1,342,000 | – | 157,176 | +100.0% | 2.33% | – | |
| NVRO | Sell | NEVRO CORP | $1,269,000 | -66.0% | 12,161 | -76.0% | 2.21% | -67.7% |
| New | FLAMEL TECHNOLOGIESadr | $716,000 | – | 57,769 | +100.0% | 1.24% | – | |
| New | GALAPAGOS NVadr | $404,000 | – | 6,250 | +100.0% | 0.70% | – | |
| New | QUEST DIAGNOSTICS | $398,000 | – | 4,700 | +100.0% | 0.69% | – | |
| New | GLAUKOS CORP | $386,000 | – | 10,233 | +100.0% | 0.67% | – | |
| PCRX | Exit | PACIRA PHARMACEUTICALS | $0 | – | -41,707 | -100.0% | -2.58% | – |
| ALR | Exit | ALERE INC | $0 | – | -63,905 | -100.0% | -4.88% | – |
| DGX | Exit | QUEST DIAGNOSTICS INC | $0 | – | -34,843 | -100.0% | -5.20% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL-SP ADRadr | $0 | – | -83,502 | -100.0% | -7.68% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.